26 Pulmonary Hypertension Clinical Trials in Denver, CO (2026)

Q: How do I join a clinical trial in Denver?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you.

Recruiting Pulmonary Hypertension Studies in Denver

NCT01334476Recruiting

VISN 19 MIRECC Research Database

The VISN 19 MIRECC is involved in research concerned with suicide prevention in high risk populations (e.g., history of traumatic brain injury, post-traumatic stress disorder); Recruitment for future ...

Denver, CO5,000 participantsVA Eastern Colorado Health Care System

View Study Details

NCT06136559Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma...

Denver, COPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06388421Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD)....

Denver, CO900 participantsUnited Therapeutics

View Study Details

NCT06911632Recruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk ...

Denver, CONA900 participantsTempus AI

View Study Details

NCT07479797Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) afte...

Denver, COPHASE3550 participantsKite, A Gilead Company

View Study Details

NCT07226843Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously t...

Denver, COPHASE1460 participantsEli Lilly and Company

View Study Details

NCT06750289Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatm...

Denver, COPHASE3400 participantsAstraZeneca

View Study Details

NCT05826535Recruiting

Study of LYL314 in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 ...

Denver, COPHASE1270 participantsLyell Immunopharma, Inc.

View Study Details

NCT06500273Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...

Denver, COPHASE2250 participantsAllogene Therapeutics

View Study Details

NCT04830137Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies....

Denver, COPHASE1248 participantsNurix Therapeutics, Inc.

View Study Details

NCT05082519Recruiting

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

Denver, COPHASE2240 participantsEtan Orgel

View Study Details

NCT05303064Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine...

Denver, COPHASE3220 participantsAlkermes, Inc.

View Study Details

NCT07101328Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the ...

Denver, COPHASE1215 participantsEli Lilly and Company

View Study Details

NCT07519772Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL i...

Denver, COPHASE1200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07038200Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)...

Denver, COPHASE3200 participantsAvidity Biosciences, Inc.

View Study Details

NCT05463263Recruiting

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas....

Denver, COPHASE1180 participantsStep Pharma, SAS

View Study Details

NCT06514794Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

Denver, COPHASE2125 participantsWugen, Inc.

View Study Details

NCT05648591Recruiting

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment....

Denver, COPHASE4100 participantsVanda Pharmaceuticals

View Study Details

NCT06505603Recruiting

PiMZ Longitudinal Cohort (PiMZ Logic)

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being Pi...

Denver, CO80 participantsColumbia University

View Study Details

NCT06129240Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH....

Denver, CO80 participantsLiquidia Technologies, Inc.

View Study Details

NCT05798897Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starti...

Denver, COPHASE179 participantsMarker Therapeutics, Inc.

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Denver, COPHASE152 participantsCellectis S.A.

View Study Details

NCT06534060Recruiting

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

Denver, COPHASE246 participantsMarch Biosciences Inc

View Study Details

NCT07096843Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...

Denver, COPHASE245 participantsClimb Bio, Inc.

View Study Details

NCT06544265Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refrac...

Denver, COPHASE136 participantsVerismo Therapeutics

View Study Details

NCT06532734Recruiting

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors...

Denver, CO25 participantsDenver Health and Hospital Authority

View Study Details

About Pulmonary Hypertension Clinical Trials in Denver

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 26 pulmonary hypertension clinical trials recruiting participants in Denver, CO. These studies are seeking a combined 12,101 participants. Research is being sponsored by VA Eastern Colorado Health Care System, Merck Sharp & Dohme LLC, United Therapeutics and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Denver — FAQ

Are there pulmonary hypertension clinical trials in Denver?

Yes, there are 26 pulmonary hypertension clinical trials currently recruiting in Denver, CO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Denver?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.

Are clinical trials in Denver free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 26 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated July 19, 2026 from ClinicalTrials.gov